Search

Displaying results 2581 - 2590 of 8196 in total
  1. Drug

    Poa pratensis pollen

    go.drugbank.com/drugs/DB10366
    Approved

    Poa pratensis pollen is the pollen of the Poa pratensis plant. Poa pratensis pollen is mainly used in allergenic testing.

  2. Drug

    Deucravacitinib

    go.drugbank.com/drugs/DB16650
    ApprovedInvestigational

    [A246938, A246943] This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  3. Target

    Transforming growth factor beta activator LRRC32

    go.drugbank.com/bio_entities/BE0014554
    TargetHumans

    Key regulator of transforming growth factor beta (TGFB1, TGFB2 and TGFB3) that controls TGF-beta activation by maintaining it in a latent state during storage in extracellular space (PubMed:19651619, PubMed:19750484, PubMed:22278742). As...

    Synonyms: Leucine-rich repeat-containing protein 32
  4. Drug

    Colestilan chloride

    go.drugbank.com/drugs/DB11634
    ApprovedWithdrawn

    Colestilan is an ingredient in the EMA-withdrawn product BindRen.

  5. Drug

    Nomegestrol

    go.drugbank.com/drugs/DB11636
    Approved

    Nomegestrol is an ingredient in the EMA-authorised product Zoely.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    Siagoside

    go.drugbank.com/drugs/DB12351
    Investigational

    Siagoside completed phase 2 trials for parkinson's disease (PD) treatment. Sygen appears to be beneficial in patients with severe spinal cord injury.

  7. Drug

    Metronidazole

    go.drugbank.com/drugs/DB00916
    ApprovedInvestigational

    [A181036,A181039] Metronidazole has been used as an antibiotic for several decades[L7429], with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesInternational brands: Arilin
  8. Drug

    Nirsevimab

    go.drugbank.com/drugs/DB16258
    ApprovedInvestigational

    [A254691] This is due to a modification in the Fc region of nirsevimab that grants it a longer half-time compared to typical monoclonal antibodies. … In addition, nirsevimab was developed as a single-dose treatment for all infants experiencing their first RSV season, whereas palivizumab requires five monthly doses to cover an RSV season.

  9. Drug

    Indacaterol

    go.drugbank.com/drugs/DB05039
    ApprovedInvestigational

    Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  10. Drug

    Phenindione

    go.drugbank.com/drugs/DB00498
    ApprovedInvestigational

    An indandione that has been used as an anticoagulant. Phenindione has actions similar to warfarin, but it is now rarely employed because of its higher incidence of severe adverse effects.